Savara Inc. Enters Material Definitive Agreement
Ticker: SVRA · Form: 8-K · Filed: Feb 16, 2024 · CIK: 1160308
| Field | Detail |
|---|---|
| Company | Savara Inc (SVRA) |
| Form Type | 8-K |
| Filed Date | Feb 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-event
TL;DR
**Savara Inc. just inked a major deal on Feb 13, signaling a big move for the pharma company!**
AI Summary
Savara Inc. entered into a material definitive agreement on February 13, 2024, as reported in their 8-K filing. The filing indicates a significant corporate event for the pharmaceutical preparations company, which is headquartered in Langhorne, PA. This agreement is a key development for Savara Inc., formerly known as Mast Therapeutics, Inc., ADVENTRX PHARMACEUTICALS INC, and BIOKEYS PHARMACEUTICALS INC.
Why It Matters
This filing signals a significant corporate action for Savara Inc., potentially impacting its strategic direction, financial health, or operational capabilities in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement without disclosing its specifics, which introduces uncertainty about its potential positive or negative impact.
Key Players & Entities
- Savara Inc. (company) — Registrant
- Mast Therapeutics, Inc. (company) — Former company name
- ADVENTRX PHARMACEUTICALS INC (company) — Former company name
- BIOKEYS PHARMACEUTICALS INC (company) — Former company name
- February 13, 2024 (date) — Date of earliest event reported
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 13, 2024.
What is the primary item information reported in this 8-K?
The primary item information reported is "Entry into a Material Definitive Agreement."
Where is Savara Inc.'s principal executive office located?
Savara Inc.'s principal executive office is located at 1717 Langhorne Newtown Road, Suite 300, Langhorne, PA 19047.
What is Savara Inc.'s Central Index Key (CIK)?
Savara Inc.'s Central Index Key (CIK) is 0001160308.
What was Savara Inc. formerly known as before March 12, 2013?
Before March 12, 2013, Savara Inc. was formerly known as Mast Therapeutics, Inc.
Filing Stats: 662 words · 3 min read · ~2 pages · Grade level 14.4 · Accepted 2024-02-16 08:31:02
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share SVRA The Nasdaq Global Se
Filing Documents
- d775782d8k.htm (8-K) — 24KB
- 0001193125-24-038108.txt ( ) — 144KB
- svra-20240213.xsd (EX-101.SCH) — 3KB
- svra-20240213_lab.xml (EX-101.LAB) — 18KB
- svra-20240213_pre.xml (EX-101.PRE) — 11KB
- d775782d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 16, 2024 SAVARA INC. a Delaware corporation By: /s/ Dave Lowrance Dave Lowrance Chief Financial & Administrative Officer